Jpmorgan Chase & CO Protara Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.86 - $4.83 $11 - $28	6 Added 37.5%	22 $0
Q4 2023 Feb 12, 2024	BUY	$1.12 - $1.93 $5 - $9	5 Added 45.45%	16 $0
Q3 2023 Nov 14, 2023	BUY	$1.64 - $2.93 $18 - $32	11 New	11 $0
Q2 2022 Aug 11, 2022	BUY	$2.8 - $5.33 $985 - $1,876	352 New	352 $1,000
Q1 2022 May 11, 2022	SELL	$4.19 - $6.9 $4,621 - $7,610	-1,103 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$6.15 - $7.76 $42,662 - $53,831	-6,937 Reduced 86.28%	1,103 $7,000
Q3 2021 Nov 12, 2021	BUY	$6.38 - $9.3 $51,295 - $74,772	8,040 New	8,040 $56,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $25.8M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.